Study for Evaluation of Efficacy and Safety of SH L 749 to Indolent B-cell Non-Hodgkin's Lymphoma
The purpose of this study is to investigate the antitumor effect and safety of the product for relapsed or refractory indolent B-cell non-Hodgkin's lymphomas.
Non-Hodgkin's Lymphoma|Lymphoma, B-Cell|Lymphoma, Low-Grade
DRUG: Zevalin (SH L 749 , BAY86-5128)|DRUG: Zevalin (SH L 749 , BAY86-5128)
Best overall response rates (the percentage of patients who achieved PR or better response), After 9 weeks or 13 weeks|The incidence of critical toxicity, During treatment period
Safety evaluation, During treatment period|Complete response (CR or CRu) rates, After 9 weeks or 13 weeks|Progression-free survival (PFS), After end of study
The study has previously been posted by Schering AG, Germany. Schering AG, Germany has been renamed to Bayer Schering Pharma AG, Germany.Bayer Schering Pharma AG, Germany is the sponsor of the trial.